Delivery efficacy of a vibrating mesh nebulizer and a jet nebulizer under different configurations

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 23, Issue 6, 2010, Pages 389-396

  Pitance, Laurent ^a   Vecellio, Laurent ^b   Leal, Teresinha ^a   Reychler, Gregory ^a   Reychler, Herve ^a   Liistro, Giuseppe ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

amikacin; jet nebulizer; lung deposition; mesh nebulizer; nebulization

Indexed keywords

AMIKACIN;

ADULT; ARTICLE; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG URINE LEVEL; GRAVIMETRY; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; MALE; NEBULIZER; NORMAL HUMAN; POLARIZATION; TUBE;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; AMIKACIN; ANTI-BACTERIAL AGENTS; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; HUMANS; MALE; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; VIBRATION;

EID: 78649958305     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2010.0816     Document Type: Article

References (41)

1. Stahlhofen W, Gebhart J, and Heyder J: Experimental determination of the regional deposition of aerosol particles in the human respiratory tract. Am Ind Hyg Assoc J. 1980;41:385-398.
2. Nikander K, Berg E, and Smaldone GC: Jet nebulizers versus pressurized metered dose inhalers with valved holding chambers: effects of the facemask on aerosol delivery. J Aerosol Med. 2007;20(Suppl 1):S46-S55.
3. Erzinger S, Schueepp KG, Brooks-Wildhaber J, Devadason SG, and Wildhaber JH: Facemasks and aerosol delivery in vivo. J Aerosol Med. 2007;20(Suppl 1):S78-S83.
4. Lin HL, Restrepo RD, Gardenhire DS, and Rau JL: Effect of face mask design on inhaled mass of nebulized albuterol, using a pediatric breathing model. Respir Care. 2007;52:1021-1026.
5. Newman SP, Woodman G, and Clarke SW: Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern. Thorax. 1988;43:318-322.
6. Martonen TB, and Katz IM: Deposition patterns of aerosolized drugs within human lungs: effects of ventilatory parameters. Pharm Res. 1993;10:871-878.
7. Hakkinen AM, Uusi-Heikkila H, Jarvinen M, Saali K, and Karhumaki L: The effect of breathing frequency on deposition of drug aerosol using an inhalation-synchronized dosimeter in healthy adults. Clin Physiol. 1999;19:269-274.
8. Valberg PA, Brain JD, Sneddon SL, and LeMott SR: Breathing patterns influence aerosol deposition sites in excised dog lungs. J Appl Physiol. 1982;53:824-837.
9. Rau JL, Ari A, and Restrepo RD: Performance comparison of nebulizer designs: constant-output, breath-enhanced, and dosimetric. Respir Care. 2004;49:174-179.
10. Coates AL, Allen PD, MacNeish CF, Ho SL, and Lands LC: Effect of size and disease on estimated deposition of drugs administered using jet nebulization in children with cystic fibrosis. Chest. 2001;119:1123-1130.
11. Coates AL, MacNeish CF, Lands LC, Meisner D, Kelemen S, and Vadas EB: A comparison of the availability of to-bramycin for inhalation from vented vs unvented nebulizers. Chest. 1998;113:951-956.
12. O'Callaghan, C.: Problems with drug delivery from nebulizers and spacers. J Aerosol Med. 2005;8:301-302.
13. Corcoran TE, Shortall BP, Kim IK, Meza MP, and Chigier N: Aerosol drug delivery using heliox and nebulizer reservoirs: results from an MRI-based pediatric model. J Aerosol Med. 2003;16:263-271.
14. Piper SD: In vitro comparison of the circulaire and AeroTee to a traditional nebulizer T-piece with corrugated tubing. Respir Care. 2000;45:313-319.
15. Pisut FM: Comparison of medication delivery by T-nebulizer with inspiratory and expiratory reservoir. Respir Care. 1989;34:985-988.
16. Corcoran TE, Dauber JH, Chigier N, and Iacono AT: Improving drug delivery from medical nebulizers: the effects of increased nebulizer flow rates and reservoirs. J Aerosol Med. 2002;15:271-282.
17. Lass JS, Sant A, and Knoch M: New advances in aerosolised drug delivery: vibrating membrane nebuliser technology. Expert Opin Drug Deliv. 2006;3:693-702.
18. Bakuridze L, Andrieu V, Dupont C, and Dubus JC: Does repeated disinfection of the e-Flow rapid nebulizer affect in vitro performance?J Cyst Fibros. 2007;6:309-310.
19. Rottier BL, Erp CJ, Sluyter TS, Heijerman HG, Frijlink HW, and Boer AH: Changes in performance of the Pari eFlow((R)) Rapid and Pari LC Plus() during 6 months use by CF patients. J Aerosol Med Pulm Drug Deliv 2009;23:236-269.
20. Dopfer R, Brand P, Mullinger B, Hunger T, Haussermann S, Meyer T, Scheuch G, and Siekmeier, R: Inhalation of to-bramycin in patients with cystic fibrosis: comparison of two methods. J Physiol Pharmacol. 2007;58(Suppl 5):141-154. (Pubitemid 351346663)
21. Vecellio L: The mesh nebuliser: a recent technical innovation for aerosol therapy. Breathe. 2009;2:253-260.
22. Reychler G, Bosschaerts M, Chevaillier J, Gaspar V, Lessire F, Opdekamp C, Van Ginderdeuren F, Vanlaethem S, Vreys M, and Vrijsen B: Inhalation equipment hygiene: a Belgian national survey. J Aerosol Med Pulm Drug Deliv. 2009;22:239-243.
23. Cheer SM, Waugh J, and Noble S: Inhaled tobramycin (TOBI): a review of its use in the management of Pseudo-monas aeruginosa infections in patients with cystic fibrosis. Drugs. 2003;63:2501-2520.
24. Campbell PW III, and Saiman L: Use of aerosolized antibiotics in patients with cystic fibrosis. Chest. 1999;116:775-788. (Pubitemid 29428499)
25. Majoral C, Vecellio L, Grimbert D, De Monte M, le Guellec C, Ingremeau V, Minois C, Cordeau E, Paintaud G, Steinberg A, and Diot P: New ipratropium formulation to decrease nebulization time. Respir Med. 2007;101:237-245.
26. Standaert TA, Vandevanter D, Ramsey BW, Vasiljev M, Nardella P, Gmur D, Bredl C, Murphy A, and Montgomery AB: The choice of compressor effects the aerosol parameters and the delivery of tobramycin from a single model nebu-lizer.J Aerosol Med. 2000;13:147-153.
27. Morrow PE: Conference on the scientific basis of respiratory therapy. Aerosol therapy. Aerosol characterization and deposition. Am Rev Respir Dis. 1974;110:88-99.
28. Vecellio None L, Grimbert D, Bordenave J, Benoit G, Furet Y, Fauroux B, Boissinot E, de Monte M, Lemarie E, and Diot P: Residual gravimetric method to measure nebulizer output. J Aerosol Med. 2004;17:63-71.
29. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, and Wanger J: Standardisation of spirometry. Eur Respir J. 2005;26:319-338.
30. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, and Yernault JC: Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J. 1993;16(Suppl):5-40.
31. Reychler G, Wallemacq P, Rodenstein DO, Cumps J, Leal T, and Liistro G: Comparison of lung deposition of amikacin by intrapulmonary percussive ventilation and jet nebuliza-tion by urinary monitoring. J.Aerosol Med. 2006;19:199-207.
32. Coates AL, Allen PD, MacNeish CF, Ho SL, and Lands LC: Effect of size and disease on estimated deposition of drugs administered using jet nebulization in children with cystic fibrosis. Chest. 2001;119:1123-1130.
33. Vecellio L, Kippax P, Rouquette S, and Diot P: Influence of realistic airflow rate on aerosol generation by nebulizers. Int J Pharm. 2009;371:99-105.
34. Wilson RS, and Muers MF: Running a domiciliary nebuliser service. Thorax. 1997;52(Suppl 2):S104-S106.
35. macokinetics and safety of tobramycin administered by the PARI eFlow((R)) rapid nebulizer in cystic fibrosis. J Cyst Fibros. 2009;8:332-337.
36. Coates AL, Green M, Leung K, Chan J, Ribeiro N, Louca E, Ratjen F, Charron M, Tservistas M, and Keller M: Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot project. Pediatr Pulmonol. 2008;43:753-759.
37. Diot P, Palmer LB, Smaldone A, DeCelie-Germana J, Grim-son R, and Smaldone GC: RhDNase I aerosol deposition and related factors in cystic fibrosis. Am J Respir Crit Care Med. 1997;156:1662-1668.
38. Neale MG, Brown K, Hodder RW, and Auty RM: The pharmacokinetics of sodium cromoglycate in man after intravenous and inhalation administration. Br J Clin Pharmacol. 1986;22:373-382.
39. Clark AR: The use of laser diffraction for the evaluation of the aerosol clouds generated by medical nebulizers. Int J Pharmaceut. 1995;115:69-78.
40. O'Riordan TG, and Amram JC: Effect of nebulizer configuration on delivery of aerosolized tobramycin. J Aerosol Med. 1997;10:13-23.
41. O'Callaghan C, and Barry PW: The science of nebulised drug delivery. Thorax. 1997;52(Suppl 2):S31-S44.